Safety Monitoring after the BNT162b2 COVID-19 Vaccine among Adults Aged 75 Years or Older
Open Access
- 1 January 2021
- journal article
- research article
- Published by XMLink in Journal of Korean Medical Science
- Vol. 36 (45)
Abstract
Choi YY, et al. J Korean Med Sci. 2021 Nov;36(45):e318. https://doi.org/10.3346/jkms.2021.36.e318Keywords
Funding Information
- National Medical Center (NMC2021)
This publication has 19 references indexed in Scilit:
- First Month of COVID-19 Vaccine Safety Monitoring — United States, December 14, 2020–January 13, 2021MMWR. Morbidity and Mortality Weekly Report, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineNew England Journal of Medicine, 2020
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine CandidatesNew England Journal of Medicine, 2020
- Efficacy and safety of COVID-19 vaccines in older peopleAge and Ageing, 2020
- Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, ChinaJAMA Internal Medicine, 2020
- Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort studyEuropean Respiratory Journal, 2020
- Assessment of sex-specific differences in adverse events following immunization reporting in Ontario, 2012–15Vaccine, 2017
- Aging and sex hormones in malesVirulence, 2016
- Sex-based differences in immune function and responses to vaccinationTransactions of the Royal Society of Tropical Medicine and Hygiene, 2015
- The Xs and Y of immune responses to viral vaccinesThe Lancet Infectious Diseases, 2010